Generic and innovative drugs market in CIS countries 2012. Russia, Ukraine and Kazakhstan Development forecasts for 2012-2014

Generic and innovative drugs market in CIS countries 2012. Russia, Ukraine and Kazakhstan

Development forecasts for 2012-2014

The report provides a comprehensive analysis of the markets in three CIS countries: Russia, Ukraine and Kazakhstan. It covers all the major segments of the generic and innovative medicines market, with forecasts for the period 2012-2014.  

The document explains the effects of recent major legal changes in the countries, which are expected to exert a powerful influence on both segments.

Key factors driving market growth and direction are described in detail, including reimbursement and pricing policies and drug patent expiry and data exclusivity periods in each country.

Profiles of largest generic and innovative drug manufacturers on the regional scale are included in this publication, as well as each country’s policies in dealing with the complications of counterfeit medicines. 

 

Core report topics include

  • Value of the generic drug market in CIS countries, 2009-2014
  • Value of the innovative drug market in CIS countries, 2009-2014
  • Size of the generic drug market in each country, with development forecasts for 2012-2014
  • Size of the innovative drug market in each country, along with development forecasts for 2012-2014
  • Market share of the generic/innovative drug market in CIS and in the covered countries
  • Regulations regarding prices of non-reimbursed and reimbursed medicines
  • VAT rates on medicines
  • Average and official price mark-ups for medicines
  • Characteristics of reimbursement systems
  • Structure of the reimbursement process
  • Expected upcoming changes to the generic and innovative drug markets, as well as in the reimbursement segment
  • The latest changes to reimbursement lists and vital and essential drugs lists; likely upcoming changes
  • Drug patent expiry and data exclusivity periods
  • Best-selling generic and innovative medicines
  • Details on the largest generic and innovative drug manufacturers in each country and in the CIS region as a whole
  • Counterfeit medicines – information on market share, policies of each country toward these medications, etc… 

….in each of the CIS countries covered in this document: Russia, Ukraine and Kazakhstan.

 

The report provides answers to pertinent questions like these

  • What is the value of the generic and innovative drug market in CIS 2009-2014?
  • What is the market size of the generic and innovative drug market in Russia, Ukraine and/or Kazakhstan?
  • In which countries will the generic drug market develop fastest between 2012 and 2014?
  • In which countries will the innovative drug market develop fastest between 2012 and 2014?
  • What are the attitudes of patients and doctors in these countries toward generic and innovative medicines?
  • What are the regulations with regard to prices of non-reimbursed and reimbursed medicines in CIS countries?
  • How does the reimbursement system function in each covered CIS country?
  • Which reforms affecting the generic and innovative drug segments have recently been implemented in CIS countries?
  • What is the structure of the reimbursement process in each CIS country?
  • How is the generic and innovative drug market in general, and the reimbursement segment in particular, expected to change in the coming months?
  • Which medicines have been recently included on or removed from reimbursement lists in each CIS country?
  • What changes to the reimbursement lists of medicines can be expected in CIS countries in the near future?
  • What are the drug patent expiry periods for each of the CIS countries?
  • How long are the data exclusivity periods in each of the CIS countries?
  • Which are best-selling generic and innovative medicines in the CIS region?
  • Which are the largest generic and innovative drug manufacturers in each country and across the overall CIS region?

 

What makes this report especially valuable?

  • Detailed data and descriptions of market conditions in each of the three CIS countries, along with comparative analysis
  • Solid development forecasts for the generic and innovative drug market for 2012-2014
  • A wide scope of analysis that includes reimbursement and pricing policies
  • A vast amount of information on the generic and innovative drug markets in CIS from a variety of diverse sources, gathered into  one competitively priced publication.

 

Issues of importance in the current market

This report examines current and upcoming events and their effects on market activity, such as:

  • Progress of the plan in Ukraine to introduce the reimbursement system, with the pilot set to begin in 2012
  • The Pharma 2020 strategy in Russia, which supports domestic industry and forces foreign manufacturers to locate factories within the country
  • Progress toward the upcoming deadlines for GMP (Good Manufacturing Practice) implementation in Kazakhstan.

 

Brands analysed in this report

Berlin-Chemie/Menarini, Dr. Reddy’s, Egis, Farmak, Gedeon Richter, Krka, Pharmstandard, Ranbaxy/Daiichi Sankyo, Stada, Teva, Sanofi, Novartis, Nycomed, Servier, GlaxoSmithKline, Bayer, Pfizer, Roche.

 

This publication is most useful to industry professionals when

  • Beginning operations in the generic drug segment in CIS countries
  • Beginning operations in innovative drug segment in CIS countries
  • Developing a balanced product portfolio of generic and/or innovative medicines
  • Analyzing  a specific CIS country’s policies with regard to generic and/or innovative medicines
  • Monitoring the most recent changes to the reimbursement/vital and essential drugs lists in CIS countries
  • Estimating growth potential of generic and/or innovative medicines in the CIS region and/or in specific CIS countries
  • Preparing market forecasts on the generic drug segment in CIS and/or in specific countries
  • Making projections about conditions in the innovative drug segment in CIS and/or in specific countries.

 

This report has been written for key decision makers and professionals, such as

  • Manufacturers and distributors of generic and/or innovative medicines
  • Companies planning to enter the CIS pharmaceutical market – either the whole region or an individual country
  • Consulting, research and analyst firms
  • Government institutions, embassies, universities and research institutes
  • Chambers of commerce, trade and industry organisations
  • Financial institutions (banks, brokerage houses, investment funds, private equity funds).

 

Extract from this report

  • In Russia in both subgroups – generic and innovative medicines – there will be an increase in domestically-manufactured medicines on the market, in line with Pharma 2020 programme assumptions. Many global pharmaceutical manufacturers are planning to establish their production facilities in Russia. These include Novartis, AstraZeneca and Novo Nordisk, in the innovative subgroup, and Krka and Teva in the generic subgroup. Russian manufacturers also intend to expand their production facilities in the country. In our opinion, however, domestic production will focus mainly on biosimilars, high-standard generic equivalents of original medicines or the so-called “me-too” projects (the manufacture of drugs which have an original patented formula which is similar in structure to the molecule of the class founder).
  • According to a number of market players (asked in interviews conducted especially for the purpose of this report), the market share of generic drugs produced by Ukrainian manufacturers will also continue to grow because they are appropriately priced. Original drugs are perfect in terms of quality, but demand is not strong at present because of the high prices. As a result, there will be a reduction in the share of original medicines in terms of volume and value on the overall market over the next three years. 

 

Market commentary by expert

CIS countries hold huge but as yet unused potential for pharmaceutical manufacturers. Spending on medicines per capita is extremely low, and appears to be the result of a lack of developed reimbursement systems and an oversized share of old, obsolete drugs on the market. This situation is expected to change gradually, over time, in most CIS countries. This report explores the market characteristics of the most attractive countries in the CIS region (Russia, Kazakhstan, Ukraine), and aids companies entering or already active in the market by providing the crucial information needed to plan successful strategies for this region.

Monika Stefańczyk, Head Pharmaceutical market Analyst

 

We use PMR's services due to their analysts' extensive experience in market analysis, their high quality and level of engagement in the market research carried out for us. We consider PMR a competent and professional company and recommend them as a reliable partner in the area of economic information and market analysis. Senior Trade and Investment Adviser, British Embassy in Warsaw
We consider PMR a competent and professional company. PMR analysts understand our needs clearly and their services have fully met our expectations. I strongly recommend the company as a reliable partner in providing economic information and market analysis. General Manager, Sanofi-Synthelabo
PMR's analysts understand our needs well and the standard of their service has always fully met our expectations. We are looking forward to cooperating with PMR in the future as well. Senior Trade and Investment Adviser, British Embassy in Warsaw
It's a great pleasure to cooperate with PMR because of its analysts' wealth of experience in understanding the local market. We consider PMR a competent and professional company which helps us conduct our business. I would also like to state that PMR's team is always ready to respond to emerging customer needs. We can recommend it as a reliable partner. Business Analyst, Hilti Distribution, Russia
As a London-based company, with operations abroad, we looked for the best-in-class Market Intelligence supplier. PMR brought us quality reports that improved our CEE market knowledge and understanding. Development Manager, GVA Grimley
Sanofi-Aventis group regularly order PMR's reports and newsletters concerning the Polish pharmaceutical market. We use PMR's services because of the wealth of experience of its analysts in undertaking market analysis and a high level of quality and involvement in the field of market research. General Manager, Sanofi-Synthelabo
PMR provides a good service and is always open to discussion. All reports are well structured & are always on time. Member of the Managment Board, SCA Hygiene Products
PMR reports are a serious contribution to the market overview picture, focusing our attention on key events in the industry as well as highlighting both general and specific market indicators. Together, these components are the base for our future forecasts of construction market development and help us to plan our sales. Market Analyst, Alpha Cement

  1. Report methodology p. 11

  2. Executive summary p. 15

    • Reimbursement and pricing policies p. 15
    • Key manufacturers and best-selling medicines p. 16
      • Drug patent expiry and data exclusivity periods p. 16
    • CIS generic and innovative drug market value p. 17
      • Russia p. 19
      • Ukraine p. 20
      • Kazakhstan p. 21
  3. Characteristics of generic and innovative drug markets in Russia, Ukraine and Kazakhstan p. 23

    • Share of Russia, Ukraine and Kazakhstan as a proportion of generic and innovative drug subgroups in CIS p. 23
      • Share of generic and innovative medicines as a proportion of the pharmaceutical market p. 24
    • Forecasts for generic and innovative medicines for 2012-2014 p. 25
    • Russia p. 27
      • Main trends and events on generic and innovative drug market p. 27
      • Market size p. 31
      • Share of pharmaceutical market p. 33
      • Market value and forecasts 2007-2014 p. 35
    • Ukraine p. 37
      • Main trends and events on generic and innovative drug market p. 37
      • Market size p. 39
      • Share of pharmaceutical market p. 40
      • Market value and forecasts 2007-2014 p. 44
    • Kazakhstan p. 46
      • Main trends and events on generic and innovative drug market p. 46
      • Share of pharmaceutical market p. 48
      • Market value and forecasts for 2012-2014 p. 49
  4. Best-selling drugs in CIS countries p. 51

    • Russia p. 51
      • Pharmacy market p. 51
      • Hospital market p. 52
      • Reimbursement subgroup p. 53
    • Ukraine p. 54
      • Pharmacy market p. 54
      • Hospital market p. 54
    • Kazakhstan p. 55
      • Pharmacy market p. 55
      • Hospital market p. 57
  5. Drug patent expiry and data exclusivity periods in CIS p. 59

    • Russia p. 59
    • Ukraine p. 60
    • Kazakhstan p. 61
  6. Counterfeit medicines in CIS p. 63

    • Russia p. 63
      • Market size p. 63
      • Categories of counterfeit drugs p. 64
      • Legal environment p. 64
    • Ukraine p. 64
      • Market size p. 64
      • Categories of counterfeit drugs p. 65
      • Legal environment p. 65
    • Kazakhstan p. 66
      • Market size p. 66
      • Categories of counterfeit drugs p. 66
      • Legal environment p. 66
  7. Reimbursement and pricing policies in Russia, Ukraine and Kazakhstan p. 67

    • Russia p. 67
      • Pricing policy p. 67
      • Reimbursement policies p. 76
    • Ukraine p. 87
      • Pricing policy p. 87
      • Reimbursement policies p. 97
    • Kazakhstan p. 101
      • Pricing policy p. 101
    • Reimbursement policy p. 104
      • Reimbursement system p. 104
      • Reimbursement process p. 105
      • Latest changes to the reimbursed drug lists p. 105
  8. Key manufacturers in CIS countries p. 109

    • Profiles of selected leading generic drug manufacturers p. 109
      • Berlin-Chemie/Menarini p. 109
      • Dr. Reddy’s p. 112
      • Egis p. 113
      • Farmak p. 115
      • Gedeon Richter p. 117
      • Krka p. 121
      • Pharmstandard p. 126
      • Ranbaxy/Daiichi Sankyo p. 132
      • Stada p. 134
      • Teva p. 137
    • Profiles of selected leading innovative drug manufacturers p. 140
      • Sanofi p. 140
      • Novartis p. 145
      • Nycomed p. 149
      • Servier p. 152
      • GlaxoSmithKline p. 153
      • Bayer p. 158
      • Pfizer p. 161
      • Roche p. 164
    • Key players in Russia p. 166
      • Pharmacy market p. 166
      • Reimbursement subgroup p. 167
      • Hospital market p. 168
      • Major events associated with generic and innovative manufacturers p. 169
    • Key players in Ukraine p. 174
      • Pharmacy market p. 174
      • By value p. 174
      • By volume p. 175
      • Hospital market p. 176
      • Major events associated with generic and innovative manufacturers p. 177
    • Key players in Kazakhstan p. 179
      • Pharmacy market p. 179
      • Hospital market p. 180
      • Major events associated with generic and innovative manufacturers p. 181
  9. List of graphs p. 183

  10. List of tables p. 189

  11. About PMR p. 193

  12. Contact PMR p. 194

List of graphs

  1. CAGR for innovative and generic drugs in CIS countries analysed (%), 2012-2014      17
  2. Value (€ bn) and y-o-y change (%) of the CIS generic drug market, 2010-2014      18
  3. Value (€ bn) and y-o-y change (%) of the CIS innovative drug market, 2010-2014      18
  4. Share of countries analysed as a proportion of the generic drug market in CIS (%), by value, 2010-2011      23
  5. Share of countries analysed as a proportion of the innovative drug market in CIS (%), by value, 2010-2011      24
  6. Share of generic and innovative drugs as a proportion of the pharmaceutical markets in CIS countries analysed (%), by value, 2011      24
  7. CAGR for innovative and generic medicines in CIS countries analysed (%), 2012-2014      25
  8. Value (€ bn) and y-o-y change (%) of the CIS generic drug market, 2010-2014      26
  9. Value (€ bn) and y-o-y change (%) of the CIS innovative drug market, 2010-2014      26
  10. Attitude of pharmacists toward innovative and generic drugs in Russia (%), 2010      27
  11. Factors which influence pharmacists when recommending the equivalents of drugs in Russia (%), 2010      27
  12. Sales value (RUB bn) of original, biological and generic drugs in seven disease categories programme in Russia, Jan-Aug 2010 – Jan-Aug 2011      32
  13. Sales value (RUB bn) of original, biological, generic and other drugs in ONLS programme in Russia, Jan-Aug 2010 – Jan-Aug 2011      33
  14. Share of generic, original and biological foreign and local drugs as a proportion of Russian pharmacy market (%), by value, H1 2010-H1 2011      33
  15. Share of imported, essential, original and generic drugs as a proportion of Russian hospital drug subgroup (%), by value and volume, H1 2011      34
  16. Share of local, essential, generic and seven disease categories subgroups of drugs as a proportion of Russian reimbursed drug subgroup (%), by value and volume, H1 2011      34
  17. Value (RUB bn) and y-o-y change (%) of the Russian generic drug market, 2007-2014      35
  18. Value (RUB bn) and y-o-y change (%) of the Russian innovative drug market, 2005-2014      36
  19. Market volume (million packages) and y-o-y change (%) in unbranded generics, branded generics and original drug subgroups in Ukraine, pharmacy sales, H1 2008-H1 2011      40
  20. Shares of generic and innovative drugs as a proportion of the pharmacy market in Ukraine (%), by volume, Q1-Q3 2009 – Q1-Q3 2011      40
  21. Shares of generic and innovative drugs as a proportion of the hospital market in Ukraine (%), by volume, Q1-Q3 2009 – Q1-Q3 2011      41
  22. Share of domestic and imported branded generic medicines in Ukraine (%), by volume, H1 2008-H1 2011      41
  23. Share of domestic and imported unbranded generic medicines in Ukraine (%), by volume, H1 2008-H1 2011      42
  24. Shares of generic and innovative drugs as a proportion of the pharmacy market in Ukraine (%), by value, Q1-Q3 2009 – Q1-Q3 2011      42
  25. Shares of generic and innovative drugs as a proportion of the hospital market in Ukraine (%), by value, Q1-Q3 2009 – Q1-Q3 2011      43
  26. Share of domestic and imported branded generic medicines in Ukraine (%), by value, H1 2008-H1 2011      43
  27. Share of domestic and imported unbranded generic medicines in Ukraine (%), by value, H1 2008-H1 2011      44
  28. Value (UAH bn) and y-o-y change (%) of the Ukrainian generic drug market, 2009-2014      45
  29. Value (UAH bn) and y-o-y change (%) of the Ukrainian innovative drug market, 2009-2014      46
  30. Shares of generic and innovative drugs as a proportion of the pharmacy market in Kazakhstan (%), by volume, 2010      48
  31. Shares of generic and innovative drugs as a proportion of the pharmacy market in Kazakhstan (%), by volume, 2011      48
  32. Shares of generic and innovative drugs as a proportion of the pharmacy market in Kazakhstan (%), by value, 2010      49
  33. Value (KZT bn) and y-o-y change (%) of the generic drug market in Kazakhstan, 2010-2014      50
  34. Value (KZT bn) and y-o-y change (%) of the innovative drug market in Kazakhstan, 2010-2014      50
  35. Sales breakdown of medicines not listed as ZHNVLP in Russia (%), by value, 2009-2011      68
  36. Sales value of medicines not listed as ZHNVLP in Russia ($ bn), pharmacy market, 2009-2011      70
  37. Breakdown of prices of vital and essential drugs in Russia, 2012      71
  38. Sales breakdown of ZHNVLP subgroup in Russia (%), by value, 2009-2011      71
  39. Sales value of ZHNVLP subgroup in Russia ($ bn), 2009-2011      72
  40. Drug price breakdown in the ONSL programme in Russia, by value, H1 2010-H1-2011      73
  41. Drug price breakdown in the ONSL programme in Russia, by volume, H1 2010-H1 2011      73
  42. Sales value of hospital drug subgroup in Russia ($ bn) and y-o-y change (%), 2010-2012      74
  43. Sales volume of hospital drug subgroup in Russia (billion packages) and y-o-y change (%), 2010-2012      75
  44. Average price per packet of medicine in hospital drug subgroup in Russia ($), 2010-2011      75
  45. Drug supply state funding system in Russia, 2012      76
  46. Sales value in the ONSL programme in Russia ($ bn) and y-o-y change (%), 2010-2012      78
  47. Sales volume (million packages) in the ONSL programme in Russia, 2010-2012      78
  48. Sales value in the VZN programme in Russia ($ bn) and y-o-y change (%), 2010-2012      79
  49. Sales volume (million packages) in the VZN programme in Russia and y-o-y change (%), 2010-2012      79
  50. Drug reimbursement process in Russia – placing of drugs on the DLO list, 2011      81
  51. Drug reimbursement process in Russia – drug provision within a DLO subgroup, 2011      82
  52. Origin of medicines on the ZHNVLP list in Russia, 2012      83
  53. Origin of medicines on the vital and essential drug list (ZHNVLP), 2011      85
  54. Origin of medicines on the vital and essential drug list (ZHNVLP), 2010      86
  55. Number and y-o-y change of INNs on the ZHNVLP list in Russia, 2009-2012      87
  56. Breakdown of the Ukrainian pharmacy market by drug price, by volume, Q1-Q3 2011      88
  57. Breakdown of the Ukrainian pharmacy market by drug price, by value, Q1-Q3 2011      88
  58. Breakdown of the Ukrainian hospital market by drug price, by volume, Q1-Q3 2011      89
  59. Breakdown of the Ukrainian hospital market by drug price, by value, 2011      89
  60. Y-o-y changes (%) in average prices of original and generic drugs in Ukraine, pharmacy market, H1 2010-H1 2011      90
  61. Average price per packet of medicine in Ukraine (UAH), overall pharmaceutical market, imported and domestic drugs, 2010-2011      90
  62. Prices of generic and innovative foreign drugs in Ukraine (UAH), H1 2008-H1 2011      91
  63. Change (%) in prices of generic and innovative foreign drugs in Ukraine, H1 2008-H1 2011      91
  64. Prices of generic branded and unbranded domestic drugs in Ukraine (UAH), H1 2008-H1 2011      92
  65. Change (%) in prices of generic branded and unbranded domestic drugs in Ukraine, H1 2008-H1 2011      92
  66. Formula for calculating the price of imported medicines which enter wholesale circulation in Ukraine, 2012      93
  67. Average markups (%) in Ukraine, medicines on National Essential Drug List, 2011      94
  68. Average markups (%) in Ukraine, pharmacy market, 2011      94
  69. Average cost (UAH) of one packet of medicine on the National Essential Drug List and medicines on pharmacy market in Ukraine, 2011      94
  70. Sales value of hospital drug subgroup in Ukraine (UAH bn) and y-o-y change (%), 2009-2011      96
  71. Sales volume of hospital drug subgroup in Ukraine (million packages) and y-o-y change (%), 2009-2011      97
  72. Average price per packet of medicine in Kazakhstan ($), pharmacy market, 2010-2011      101
  73. Breakdown of pharmacy market by drug price, Kazakhstan, by value, 2011      102
  74. Sales value ($ m) and volume (million packages) of hospital drug market in Kazakhstan, Q1-Q3 2010 – Q1-Q3 2011      102
  75. Average price per packet of medicine in hospital drug market in Kazakhstan ($), Q1-Q3 2010 – Q1-Q3 2011      103
  76. Origin of medicines in hospital drug market in Kazakhstan, Q1-Q3 2011      103
  77. Average price per packet of medicine in Kazakhstan ($), out-of-pocket and reimbursed drugs, 2011      104
  78. Origin of medicines on the Essential Drug List in Kazakhstan, by volume, 2012      106
  79. Manufacturers on the Essential Drug List in Kazakhstan, by number of brands, 2012      106
  80. Berlin-Chemie/Menarini total sales in Russia ($ m) and y-o-y change (%), 2010-2011      109
  81. Berlin-Chemie/Menarini pharmacy sales in Russia (RUB bn) and y-o-y change (%), 2010-2011      110
  82. Berlin-Chemie/Menarini pharmacy sales in Ukraine ($ m) and y-o-y change (%), 2009-2011      110
  83. Berlin-Chemie/Menarini total sales in Kazakhstan ($ m) and y-o-y change (%), 2010-2011      111
  84. Dr. Reddy’s sales revenues ($ m) and y-o-y change (%) in Russia, FY 2005-H1 FY 2012      112
  85. Egis total sales in Russia (€ m) and y-o-y change (%), 2008/2009-H1 2011/2012      113
  86. Egis total sales in Ukraine (€ m) and y-o-y change (%), 2008-H1 2011/2012      114
  87. Egis total sales in Kazakhstan (€ m) and y-o-y change (%), 2008-2011      114
  88. Farmak’s net sales revenue (€ m) and y-o-y change (%), 2006-2011      115
  89. Gedeon Richter’s sales in Russia (€ m) and y-o-y change (%), 2007-Q1 2012      117
  90. Gedeon Richter’s sales in Ukraine (€ m) and y-o-y change (%), 2007-Q1 2012      118
  91. Gedeon Richter’s sales in Kazakhstan (€ m) and y-o-y change (%), 2007-2011      118
  92. Gedeon Richter’s sales in other CIS countries (€ m) and y-o-y change (%), 2007-Q1 2012      119
  93. Krka’s sales in Russia (€ m) and y-o-y change (%), 2007-Q1 2012      121
  94. Krka’s sales in Ukraine (€ m) and y-o-y change (%), 2007-Q1 2012      122
  95. Krka’s sales in Kazakhstan (€ m) and y-o-y change (%), 2008-Q1 2012      122
  96. Krka key Central and Eastern European market performance, by change in sales (%), 2011      123
  97. Pharmstandard’s total sales (RUB bn) and y-o-y change (%), 2004-Q1 2012      126
  98. Breakdown of Pharmstandard sales (%), 2011      127
  99. Breakdown of Pharmstandard sales (%), Q1 2012      127
  100. Pharmstandard’s sales (RUB m) and y-o-y change (%) in Ukraine, 2009-2011      128
  101. Pharmstandard’s sales (RUB m) and y-o-y change (%) in Kazakhstan, 2009-2011      128
  102. Ranbaxy’s sales in Russia and Ukraine ($ m) and y-o-y change (%), 2008-2011      132
  103. Stada’s sales of generic and branded products in Russia (€ m) and y-o-y change (%), 2008-2011      134
  104. Stada’s sales of generic and branded products in Ukraine (€ m) and y-o-y change (%), 2008-2011      135
  105. Stada’s sales of generic and branded products in Kazakhstan (€ m) and y-o-y change (%), 2008-2011      135
  106. Teva’s total sales in Russia ($ m) and y-o-y change (%), 2010-2011      137
  107. Teva’s pharmacy sales in Ukraine ($ m) and y-o-y change (%), 2010-2011      138
  108. Teva’s total sales in Kazakhstan ($ m) and y-o-y change (%), 2010-2011      138
  109. Sanofi’s pharmacy sales in Russia (RUB bn) and y-o-y change (%), 2010-2011      140
  110. Sanofi’s pharmacy sales in Ukraine ($ m) and y-o-y change (%), 2009-2011      141
  111. Sanofi’s pharmacy sales in Kazakhstan ($ m) and y-o-y change (%), 2010-2011      141
  112. Novartis’ pharmacy sales in Russia (RUB bn) and y-o-y change (%), 2010-2011      145
  113. Novartis’ pharmacy sales in Ukraine ($ m) and y-o-y change (%), 2010-2011      145
  114. Novartis’ pharmacy sales in Kazakhstan ($ m) and y-o-y change (%), 2010-2011      146
  115. Nycomed’s pharmacy sales in Russia (RUB bn) and y-o-y change (%), 2009-2011      149
  116. Nycomed’s pharmacy sales in Ukraine ($ m) and y-o-y change (%), 2009-2011      149
  117. Nycomed’s total sales in Kazakhstan ($ m) and y-o-y change (%), 2010-2011      150
  118. Servier’s pharmacy sales in Russia (RUB bn) and y-o-y change (%), 2010-2011      152
  119. Servier’s pharmacy sales in Ukraine ($ m) and y-o-y change (%), 2009-2011      152
  120. GSK’s total sales in Russia ($ m) and y-o-y change (%), 2010-2011      153
  121. GSK’s pharmacy sales in Ukraine ($ m) and y-o-y change (%), 2009-2011      154
  122. GSK’s total sales in Kazakhstan ($ m) and y-o-y change (%), 2010-2011      154
  123. Bayer’s pharmacy sales in Russia (RUB bn) and y-o-y change (%), 2010-2011      158
  124. Bayer’s pharmacy sales in Ukraine ($ m) and y-o-y change (%), 2009-2011      158
  125. Bayer’s total sales in Kazakhstan ($ m) and y-o-y change (%), 2010-2011      159
  126. Pfizer’s pharmacy sales in Russia (RUB bn) and y-o-y change (%), 2010-2011      161
  127. Pfizer total sales in Kazakhstan ($ m) and their y-o-y change, 2010-2011      161
  128. Roche’s total sales in Russia ($ m) and y-o-y change (%), 2010-2011      164

List of tables

  1. Comparison of VAT rates, drug price controls, reimbursement solutions, patent protection and future developments for reimbursement system in CIS countries analysed, 2012      16
  2. Drug patent expiry and data exclusivity periods in CIS countries analysed in comparison with EU, 2012      17
  3. Market volume (million packages) and y-o-y change (%) in branded generics and original drug subgroups in Russia, pharmacy sales, Q1-Q3 2010 – Q1-Q3 2011      31
  4. Top 10 best-selling innovative and generic drugs in Russia, by value, pharmacy market, 2010-2011      51
  5. Top 10 best-selling innovative and generic drugs in Russia, by value, hospital market, Q1-Q3 2010 – Q1-Q3 2011      52
  6. Top 10 best-selling innovative and generic drugs in Russia, by value, hospital market, 2011      52
  7. Top 10 best-selling innovative and generic drugs in Russia, by value, reimbursement subgroup, Q1-Q3 2010 – Q1-Q3 2011      53
  8. Top 10 best-selling innovative and generic drugs in Russia, by value, reimbursement (DLO) subgroup, 2011      53
  9. Top 10 best-selling innovative and generic drugs in Ukraine, by value, pharmacy market, 2011      54
  10. Top 20 best-selling generic and innovative drugs in Ukraine, by value, hospital market, 2009-2011      55
  11. Top 10 best-selling generic and innovative drugs in Kazakhstan, by value, pharmacy market, H1 2010-H1 2011      55
  12. Top 10 best-selling generic and innovative drugs in Kazakhstan, by value, pharmacy market, 2011      56
  13. Top 10 best-selling drugs in Kazakhstan, by volume, pharmacy market, 2011      56
  14. Top 10 best-selling generic and innovative drugs in Kazakhstan, by value, hospital market, Q1-Q3 2010 – Q1-Q3 2011      57
  15. Maximum wholesale and retail markups of vital and essential drugs in cities of federal importance and regions with established minimum and maximum markups in Russia (%), Q4 2011      70
  16. Leading VZN disease categories in Russia, by value, January-August 2010 – January-August 2011      80
  17. Share of Russian biogeneric medicines as a proportion of the value of new drugs on the Russian pharmaceutical market, by value, H1 2011      80
  18. Products launched by Gedeon Richter in the CIS countries, 2011-Q1 2012      121
  19. Pharmstandard’s best-selling Rx generic and innovative drugs in CIS, by value, 2011      130
  20. New products launched by Pharmstandard in Russia, 2011      130
  21. New products due to be introduced on the market by Pharmstandard, 2012      131
  22. Ranbaxy/Daiichi Sankyo clinical trials carried out in CIS countries analysed, June 2012      133
  23. Teva’s clinical trials carried out in CIS countries analysed, June 2012      140
  24. Sanofi’s clinical trials carried out in CIS countries analysed, May 2012      144
  25. Novartis’ clinical trials carried out in CIS countries analysed, May 2012      148
  26. Nycomed’s clinical trials carried out in CIS countries analysed, May 2012      151
  27. GlaxoSmithKline’s clinical trials carried out in CIS countries analysed, May 2012      156-157
  28. Bayer’s clinical trials carried out in CIS countries analysed, May 2012      160
  29. Pfizer’s clinical trials carried out in CIS countries analysed, May 2012      163
  30. Roche’s clinical trials carried out in CIS countries analysed, May 2012      165-166
  31. Top 10 generic and innovative pharmaceutical manufacturers in Russia, by value, pharmacy market, 2010-2011      167
  32. Top 10 generic and innovative pharmaceutical manufacturers in Russia, by value, reimbursement subgroup, Q1-Q3 2010 – Q1-Q3 2011      167
  33. Top 10 generic and innovative pharmaceutical manufacturers in Russia, by value, ONSL programme, H1 2010-H1 2011      168
  34. Top 10 generic and innovative pharmaceutical manufacturers in Russia, by value, hospital market, Q1-Q3 2010 – Q1-Q3 2011      168
  35. Examples of investments and agreements pertaining to drug production in Russia, 2011-2012      173-174
  36. Top innovative pharmaceutical manufacturers in Ukraine, by value, pharmacy market, 2011      175
  37. Top generic pharmaceutical manufacturers in Ukraine, by value, pharmacy market, 2011      175
  38. Top 10 generic pharmaceutical manufacturers in Ukraine, by volume, pharmacy market, December 2010-November 2011      176
  39. Top innovative pharmaceutical manufacturers in Ukraine, by volume, pharmacy market, December 2010-November 2011      176
  40. Top 20 generic and innovative pharmaceutical manufacturers in Ukraine, by value, hospital market, 2011      177
  41. Examples of investments and agreements pertaining to drug production in Ukraine, 2011-2012      178
  42. Top 10 generic and innovative pharmaceutical manufacturers in Kazakhstan, by value, pharmacy market, 2010-2011      179
  43. Top 10 generic and innovative pharmaceutical manufacturers in Kazakhstan, by volume, pharmacy market, 2010-2011      180
  44. Top 10 generic and innovative pharmaceutical manufacturers in Kazakhstan, by value, hospital market, Q1-Q3 2010 – Q1-Q3 2011      180
  45. Examples of investments and agreements pertaining to drug production in Kazakhstan, 2012      181